Nolan J Maloney1, Jeffrey Zhao2, Kyle Tegtmeyer2, Ernest Y Lee3,4, Kyle Cheng1. 1. Division of Dermatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 2. Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 3. David Geffen School of Medicine at UCLA, UCLA-Caltech Medical Scientist Training Program, Los Angeles, CA, USA. 4. Department of Bioengineering, UCLA, Los Angeles, CA, USA.
Abstract
Purpose: Apremilast is a phosphodiesterase-4 inhibitor FDA approved for psoriatic arthritis and moderate to severe plaque psoriasis. In recent years, multiple studies have suggested other potential uses for apremilast in dermatology. A summary of these various studies will be a valuable aid to dermatologists considering apremilast for an alternative indication.Materials and methods: The PubMed/MEDLINE and ClinicalTrials.gov databases were queried with the term 'apremilast,' with results manually screened to identify published data on off-label uses of apremilast. The article was structured by the quality of evidence available. Results: Apremilast use in dermatology beyond plaque psoriasis and psoriatic arthritis is frequently described in the literature, with a mixture of positive and negative results. Randomized controlled data is available for Behçet's disease, hidradenitis suppurativa, nail/scalp/palmoplantar psoriasis, alopecia areata, and atopic dermatitis. Conclusion: The relatively safe adverse effect profile of apremilast and its broad immunomodulatory characteristics may make it a promising option in the future for patients with difficult to treat diseases in dermatology, refractory to first line therapies, but further studies will be necessary to clarify its role.
Purpose: Apremilast is a phosphodiesterase-4 inhibitor FDA approved for psoriatic arthritis and moderate to severe plaque psoriasis. In recent years, multiple studies have suggested other potential uses for apremilast in dermatology. A summary of these various studies will be a valuable aid to dermatologists considering apremilast for an alternative indication.Materials and methods: The PubMed/MEDLINE and ClinicalTrials.gov databases were queried with the term 'apremilast,' with results manually screened to identify published data on off-label uses of apremilast. The article was structured by the quality of evidence available. Results:Apremilast use in dermatology beyond plaque psoriasis and psoriatic arthritis is frequently described in the literature, with a mixture of positive and negative results. Randomized controlled data is available for Behçet's disease, hidradenitis suppurativa, nail/scalp/palmoplantar psoriasis, alopecia areata, and atopic dermatitis. Conclusion: The relatively safe adverse effect profile of apremilast and its broad immunomodulatory characteristics may make it a promising option in the future for patients with difficult to treat diseases in dermatology, refractory to first line therapies, but further studies will be necessary to clarify its role.
Authors: Jaclyn A Kalik; Harvey Friedman; Mark A Bechtel; Alejandro A Gru; Benjamin H Kaffenberger Journal: JAMA Dermatol Date: 2017-11-01 Impact factor: 10.282
Authors: Jeffrey Crowley; Diamant Thaçi; Pascal Joly; Ketty Peris; Kim A Papp; Joana Goncalves; Robert M Day; Rongdean Chen; Kamal Shah; Carlos Ferrándiz; Jennifer C Cather Journal: J Am Acad Dermatol Date: 2017-04-14 Impact factor: 11.527
Authors: Allard R J V Vossen; Martijn B A van Doorn; Hessel H van der Zee; Errol P Prens Journal: J Am Acad Dermatol Date: 2018-07-03 Impact factor: 11.527
Authors: R Bissonnette; R Haydey; L A Rosoph; C W Lynde; M Bukhalo; J F Fowler; I Delorme; A Gagné-Henley; M Gooderham; Y Poulin; K Barber; P Jenkin; I Landells; D M Pariser Journal: J Eur Acad Dermatol Venereol Date: 2017-11-15 Impact factor: 6.166
Authors: Jean-Paul J Abboud; Alexander Whittington; Masih Ahmed; Jesse T Himebaugh; Lee A Wiley; Ahmad Haffar; John Nguyen Journal: Ophthalmic Plast Reconstr Surg Date: 2018 May/Jun Impact factor: 1.746
Authors: Ester Del Duca; Paola Morelli; Luigi Bennardo; Cosimo Di Raimondo; Steven Paul Nisticò Journal: Int J Mol Sci Date: 2020-11-10 Impact factor: 5.923
Authors: Kristin Helene Skullerud; Petter Gjersvik; Are Hugo Pripp; Erik Qvigstad; Anne Lise Ording Helgesen Journal: Trials Date: 2021-07-20 Impact factor: 2.279